Cyclin D1-negative and SOX11-positive B-cell lymphoma with CD5 and CD10 coexpression and MYC rearrangement: A diagnostic challenge

Abstract

A 66-year-old male presented with a large left renal/perirenal mass (9.7 cm) and diffuse lymphadenopathies. A biopsy showed diffuse proliferation of monotonous small to intermediate lymphocytes with irregular nuclei and condensed chromatin (upper left, 20×; upper middle, 400×). The background epithelioid histiocytes and hyalinized vessels were noted. By immunohistochemistry, the lymphocytes were positive for CD20, CD5 (upper right, 200×), CD10 (middle left, 200×), SOX11 (middle central, 200×), and BCL2, but were negative for cyclin D1 (middle right, 200×), cyclin D3, CD23, and BCL6. MYC was expressed by 10%–20% of the cells with heterogeneous intensities (lower left, 200×), and the Ki67 proliferation index was about 30% (lower middle, 200×). Cytogenetic studies revealed MYC rearrangement in 97% of cells by using MYC break-apart probes (lower right, 5′ probe in red, 3′ probe in green) but with no evidence of IGH::MYC, IGK::MYC, or IGL::MYC fusions by further evaluation by fluorescence in situ hybridization (FISH). Assessment for rearrangements by using CCND1, CCND2, CCND3, BCL2, BCL6, and IGH break-apart probes were all negative.

Based on the morphological and immunophenotypical features, this most likely represents a cyclin D1-negative mantle cell lymphoma with MYC rearrangement. SOX11 is a highly specific marker for mantle cell lymphomas, which is consistently negative in other mature B-cell lymphomas other than Burkitt lymphoma [1]. However, we were not able to demonstrate the presence of CCND1/2/3 rearrangements by break-apart FISH probes. It has been reported that cryptic insertions of immunoglobulin (IG) light chain enhancers are associated with cyclin D2/3 overexpression in cyclin D1-negative mantle cell lymphomas. Although cyclin D3 was not overexpressed in our case, cyclin D2 immunohistochemistry was not available and its overexpression cannot be excluded. In addition, a minor subset of mantle cell lymphomas lacks CCND1/2/3 rearrangements but instead shows cyclin E upregulation [2]. MYC rearrangement can be seen in about 1.5% of mantle cell lymphomas, which is associated with blastoid morphology, aggressive disease course, and CD10 expression (seen in our case) [3]. To date, all the reported MYC-rearranged mantle cell lymphoma cases are positive for cyclin D1 by immunohistochemistry. In our case, the lack of cyclin D1/3 expression and CCND1/2/3 rearrangements by break-apart FISH probes, in conjunction with the aberrant CD10 expression, confers diagnostic challenge. In addition, MYC showed rearrangement with a non-IG partner gene in this case. The translocation partners in MYC-rearranged mantle cell lymphomas are not well characterized. It remains to be explored whether the aggressive features associated with MYC-rearranged mantle cell lymphomas are preferentially seen in patients with IG::MYC (Figure 1).

Mariko Yabe designed the study and analyzed the data. Mingfei Yan analyzed the data and drafted the manuscript. Yanming Zhang performed cytogenetic study. Ahmet Dogan supervised the study. All the authors revised the manuscript.

The authors declare no conflicts of interest.

The authors received no specific funding for this work.

This study is approved by our institutional review board.

The authors have confirmed patient consent statement is not needed for this submission.

The authors have confirmed clinical trial registration is not needed for this submission.

N/a.